The presence of PEG on nanoparticles presenting the c[RGDfK]- and/or ATWLPPR peptides deeply affects the RTKs-AKT-GSK3β-eNOS signaling pathway and endothelial cells survival

Int J Pharm. 2019 Sep 10:568:118507. doi: 10.1016/j.ijpharm.2019.118507. Epub 2019 Jul 9.

Abstract

Covering the surface of a nanoparticle with polyethylene glycol (PEG) is a common way to prevent non-specific interactions but how its presence impacts on the activity of targeting ligands is still poorly documented. We synthesized a set of 9 silica nanoparticles grafted with c[RGDfK]-, a peptide targeting integrin αvß3 (cRGD), and/or with ATWLPPR, an anti-neuropilin 1 peptide (ATW). We then added various PEGs, and studied NPs binding on primary endothelial cells, the downstream activated signaling pathways and the impact on apoptosis. Our results show that the presence of PEG2000 on cRGD/ATW nanoparticles moderately improves cell binding but induces a 6000 times augmentation of AKT-dependent cell response due to the recruitment of other Receptor Tyrosine Kinases. Augmenting the length of the spacer that separates the peptides from the silica (using PEG3000) mainly resulted in a loss of specificity. Finally, the PEG-mediated hyperactivation of AKT did not protect endothelial cell from dying in the absence of serum, while its moderate activation obtained without PEG did. Finally, PEGylation of cRGD/ATW-NPs can generate nanoparticles with potent capacities to activate the AKT-GSK3β-eNOS cascade and to affect the resistance of endothelial cells to apoptosis. Thus, the impact of PEGylation should be precisely considered in order to avoid the apparition of counter-productive biological responses.

Keywords: AKT; Angiogenesis; Homomultimer and heteromultimer targeting; IGF-1R/IR; Neuropilin 1; α(v)ß(3) integrin.

MeSH terms

  • Cell Survival / drug effects
  • Cells, Cultured
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Human Umbilical Vein Endothelial Cells / drug effects*
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Nanoparticles / administration & dosage*
  • Nanoparticles / chemistry
  • Nitric Oxide Synthase Type III / metabolism
  • Oligopeptides / administration & dosage*
  • Oligopeptides / chemistry
  • Peptides, Cyclic / administration & dosage*
  • Peptides, Cyclic / chemistry
  • Polyethylene Glycols / administration & dosage*
  • Polyethylene Glycols / chemistry
  • Proto-Oncogene Proteins c-akt / metabolism
  • Receptor Protein-Tyrosine Kinases / metabolism
  • Signal Transduction / drug effects
  • Silicon Dioxide / administration & dosage*
  • Silicon Dioxide / chemistry

Substances

  • Ala-Thr-Trp-Leu-Pro-Pro-Arg
  • Oligopeptides
  • Peptides, Cyclic
  • cyclic (arginyl-glycyl-aspartyl-phenylalanyl-lysyl)
  • Polyethylene Glycols
  • Silicon Dioxide
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III
  • Receptor Protein-Tyrosine Kinases
  • Glycogen Synthase Kinase 3 beta
  • Proto-Oncogene Proteins c-akt